XT High-Tech

XT High-Tech is a clinical-stage biotechnology company headquartered in Suzhou, China, dedicated to the discovery and development of innovative targeted protein degradation (TPD) therapies. The company leverages its proprietary XT-PROTAC platform to create small molecule degraders that harness the body's natural protein disposal system to eliminate disease-driving proteins. Its current pipeline is focused on high-value targets in oncology and immunology, with lead programs targeting the androgen and estrogen receptors for the treatment of hormone-driven cancers. By focusing on degradation rather than inhibition, XT High-Tech seeks to provide more effective treatment options for patients who have developed resistance to standard-of-care therapies. The company is backed by prominent life science investors and aims to establish a leading position in the global TPD landscape.